Ponatinib Powder

Product Details

Ponatinib powder is an anticancer drug. It was approved by the US FDA in December 2012 for the treatment of adult chronic myeloid leukemia (CML) and “Philadelphia chromosome positive” (Ph+) acute lymphoblastic leukemia (ALL). It is mainly used to treat patients who are refractory to dasatinib or nilotinib, or who cannot tolerate dasatinib or nilotinib, and patients who are not suitable for subsequent treatment with imatinib. It also be used to treat patients with a genetic mutation (“T315I mutation”) that makes the patient resistant to imatinib, dasatinib, or nilotinib. It is currently the only marketed drug that is effective against the Bcr-Abl kinase T315I mutation.

Ponatinib was approved in the EU in July 2013 through a centralized approval process. Ponatinib is a third-generation multi-targeted tyrosine kinase inhibitor. Typical representatives of multi-targeted tyrosine kinase inhibitors include sunitinib, imatinib, sorafenib vatalanib base etc.

Health Benefits

Ponatinib powder is a kinase inhibitor indicated for the treatment of adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant or intolerant to prior tyrosine kinase inhibitor therapy Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to prior tyrosine kinase inhibitor therapy. This indication is based on response rate. No trials with Iclusig have demonstrated improvement in disease-related symptoms or increased survival.